PolyPid (PYPD) Non-Current Deffered Revenue (2022 - 2026)
PolyPid (PYPD) posted Non-Current Deffered Revenue of $2.5 million for Q1 2026, little changed sequentially from $2.5 million in Q4 2025, and little changed YoY from $2.5 million in Q1 2025.
PolyPid (PYPD) Non-Current Deffered Revenue (2022 - 2026) Analysis & Trends
PolyPid has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $2.5 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was little changed at $2.5 million in Q1 2026 per PYPD's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.5 million in Q3 2022 and troughed at $2.5 million in Q3 2022.
- A 5-year average of $2.5 million and a median of $2.5 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2023, down 0.0% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025, then changed by 0.0% to $2.5 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.5 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.55 Mn |
| Mar 31, 2026 | 2.55 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 2.55 Mn |
| Dec 31, 2024 | 2.55 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 2.55 Mn |
| Dec 31, 2023 | 2.55 Mn |
| Sep 30, 2023 | 2.55 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.55 Mn |